

PharmLabs San Diego Certificate of Analysis

Sample Dali's Dream - Phantom OG - 2mL Cartridge



| | | | | | | | |
|------------|----|------|----|--------------------------------|----|------------|--------|
| Delta9 THC | UI | THCa | ND | Total THC (THCa * 0.877 + THC) | UI | Delta8 THC | 44.60% |
|------------|----|------|----|--------------------------------|----|------------|--------|

Sample ID SD221215-029 (56961)

Tested for Arvida Labs

Received Dec 14, 2022

Matrix Concentrate

Reported Dec 15, 2022

Unit Mass (g) 2.0

Laboratory note: The estimated concentration of the unknown peak in the sample is 0.33%. Currently PharmLabs laboratory can not confirm an unidentified peak in your chromatogram due to interference (only with highly concentrated D8 products) from which we believe to be either (-)-d9-THC or d9-THC. At this time there are no reference standards available for (+)-d8-THC. (+)-d8-THC is a different compound from the main (-)-d8-THC cannabinoid and, therefore, these two compounds may have different efficacies. Using the most advanced instruments and techniques available, the separation of (+)-d9-THC and d9-THC is problematic for the scientific community as a whole. PharmLabs believes the unidentified peak to be a combination of (-)-d8-THC and d9-THC with the majority, if not all, of the concentration being (-)-d8-THC. Total (-)-D8 Concentration is estimated to be: 44.60%.

CANx - Cannabinoids

Analyzed Dec 15, 2022 | Instrument HPLC-VWD | Method SOP-001

The expanded Uncertainty of the Cannabinoids analysis is approximately $\pm 7.81\%$ at the 95% Confidence Level

| Analyte | LOD mg/g | LOQ mg/g | Result % | Result mg/g | Result mg/Unit | Sample photography |
|------------------------------------------------------------------------------------------------------------|----------|----------|----------|-------------|----------------|--------------------|
| 11-Hydroxy- Δ 8-Tetrahydrocannabivarin (11-Hyd- Δ 8-THCV) | 0.013 | 0.041 | ND | ND | ND | |
| Cannabidiol (CBD) | 0.006 | 0.02 | ND | ND | ND | |
| Abnormal Cannabidiol (a-CBDO) | 0.013 | 0.038 | ND | ND | ND | |
| (+/-)-9 β -hydroxy-Hexahydrocannabinol (9 β -HHC) | 0.015 | 0.045 | ND | ND | ND | |
| 11-Hydroxy- Δ 8-Tetrahydrocannabinol (11-Hyd- Δ 8-THC) | 0.015 | 0.045 | ND | ND | ND | |
| Cannabidiolic Acid (CBDA) | 0.033 | 0.16 | ND | ND | ND | |
| Cannabigerol Acid (CBGA) | 0.033 | 0.16 | 0.50 | 5.03 | 10.06 | |
| Cannabigerol (CBG) | 0.048 | 0.16 | ND | ND | ND | |
| Cannabidiol (CBD) | 0.069 | 0.229 | 4.12 | 41.20 | 82.40 | |
| 1(S)-Tetrahydrocannabinol (1(S)-H4-CBD) | 0.008 | 0.026 | ND | ND | ND | |
| 1(R)-Tetrahydrocannabinol (1(R)-H4-CBD) | 0.016 | 0.049 | ND | ND | ND | |
| Tetrahydrocannabivarin (THCV) | 0.049 | 0.162 | ND | ND | ND | |
| Δ 8-tetrahydrocannabivarin (Δ 8-THCV) | 0.021 | 0.064 | ND | ND | ND | |
| Tetrahydrocannabutol (Δ 9-THCB) | 0.01 | 0.029 | ND | ND | ND | |
| Cannabinol (CBN) | 0.047 | 0.16 | 5.94 | 59.38 | 118.75 | |
| Cannabidiphorol (CBDP) | 0.016 | 0.049 | ND | ND | ND | |
| exo-THC (exo-THC) | 0.016 | 0.8 | ND | ND | ND | |
| Tetrahydrocannabinol (Δ 9-THC) | 0.092 | 0.307 | UI | UI | UI | |
| Δ 8-tetrahydrocannabinol (Δ 8-THC) | 0.044 | 0.16 | 44.60 | 445.98 | 891.97 | |
| (6aR,9S)- Δ 10-Tetrahydrocannabinol ((6aR,9S)- Δ 10) | 0.015 | 0.8 | ND | ND | ND | |
| Hexahydrocannabinol (S Isomer) (9 β -HHC) | 0.017 | 0.8 | 12.51 | 125.12 | 250.25 | |
| (6aR,9R)- Δ 10-Tetrahydrocannabinol ((6aR,9R)- Δ 10) | 0.007 | 0.8 | ND | ND | ND | |
| Hexahydrocannabinol (R Isomer) (9 β -HHC) | 0.016 | 0.8 | 23.15 | 231.47 | 462.95 | |
| Tetrahydrocannabinolic Acid (THCA) | 0.117 | 0.389 | ND | ND | ND | |
| Δ 9-Tetrahydrocannabihexol (Δ 9-THCH) | 0.02 | 0.061 | ND | ND | ND | |
| Cannabinol Acetate (CBNO) | 0.009 | 0.027 | ND | ND | ND | |
| Δ 9-Tetrahydrocannabiphorol (Δ 9-THCP) | 0.017 | 0.8 | 4.23 | 42.33 | 84.67 | |
| Δ 8-Tetrahydrocannabiphorol (Δ 8-THCP) | 0.041 | 0.8 | ND | ND | ND | |
| Δ 8-THC-O-acetate (Δ 8-THCO) | 0.076 | 0.8 | ND | ND | ND | |
| 9(S)-HHCP (s-HHCP) | 0.013 | 0.041 | ND | ND | ND | |
| Δ 9-THC-O-acetate (Δ 9-THCO) | 0.066 | 0.8 | ND | ND | ND | |
| 9(R)-HHCP (r-HHCP) | 0.015 | 0.045 | ND | ND | ND | |
| 3-octyl- Δ 8-Tetrahydrocannabinol (Δ 8-THC-C8) | 0.021 | 0.062 | ND | ND | ND | |
| Total THC (THCa * 0.877 + Δ 9THC) | | | UI | UI | UI | |
| Total THC + Δ 8THC + Δ 10THC (THCa * 0.877 + Δ 9THC + Δ 8THC + Δ 10THC) | | | 44.60 | 445.98 | 891.97 | |
| Total CBD (CBDa * 0.877 + CBD) | | | 4.12 | 41.20 | 82.40 | |
| Total CBG (CBGa * 0.877 + CBG) | | | 0.44 | 4.41 | 8.82 | |
| Total HHC (9 β -HHC + 9 β -HHCP) | | | 35.66 | 356.60 | 713.20 | |
| Total Cannabinoids Analyzed | | | 94.99 | 949.90 | 1899.80 | |

UI Unidentified
 ND Not Detected
 N/A Not Applicable
 NT Not Reported
 LOD Limit of Detection
 LOQ Limit of Quantification
 <LOQ Detected
 >ULOL Above upper limit of linearity
 CFU/g Colony Forming Units per 1 gram
 TNTC Too Numerous to Count



DCC license: C8-0000098-LIC
 DEA license: RP0611043
 ISO/IEC 17025:2017 Acc. 85368



Scan the QR code to verify authenticity.

Authorized Signature

Brandon Starr, Quality Assurance Manager
 Thu, 15 Dec 2022 12:19:22 -0800



PharmLabs San Diego states that its Certificates of Analysis (COA) do not certify compliance with any federal, state, or local law or regulation, including but not limited to the 2018 Farm Bill. This COA is provided for informational purposes and is not intended for reliance by any party. The COA is issued for the specific lot, batch, or product identified on this COA and do not represent any other lot, batch, or product from the client. Measurement of uncertainty is available upon request and, when legally required, has been reported on the certificate. PharmLabs makes no representation or warranty, express or implied, as to the quality of the product(s) or its compliance with any applicable federal, state, or local laws and regulations. PharmLabs does not assume any responsibility for errors, omissions, or misrepresentations in such information. It is the sole responsibility of the client to determine and ensure the compliance of their product(s) with all applicable federal, state, and local laws and regulations. This COA may not be used in whole or in part for marketing, advertising, promotional, or labeling purposes without the prior written consent of PharmLabs. This COA is valid for the date of issuance and does not guarantee the stability or continued conforming of the tested product beyond that date. Any disputes arising out of or related to this COA shall be governed by the laws of the State of California, without regard to its conflict of laws principles.